InvestorsHub Logo
Followers 20
Posts 728
Boards Moderated 0
Alias Born 11/07/2003

Re: None

Tuesday, 10/24/2017 4:39:47 PM

Tuesday, October 24, 2017 4:39:47 PM

Post# of 13383
From Twitter

They have been sending out tweets referencing all meds in diabetes. The data they collect will be valuable to big Pharma. Anyone who does not think this patent pending product is going to generate huge revunue just does not understand how medical reimbursement work. Revenue will come from multiple streams. They are going to have much bigger players pushing this to a broad adoption sooner than later. That's why they can get this done with the FDA clearance and a staff of consultants. Just look in different geographies who is allowed to prescribe. It's not only Dr's. Absolutely brilliant tool for this disease and they are light years ahead of any comp.

Imagine being able to predict a patient’s current A1c level BEFORE prescribing Actos, or Avandia?

why do you even need to predict it...a blood test will tell you just fine?

An A1c test takes time and money. Plus, it’s a snapshot in time. You need to have an idea where A1c is before you can prescribe./1

Also, many healthcare providers are reimbursed for performance and in diabetes that’s the A1c level./2

If you can control A1c with an accurate dose of insulin you’re performance will improve (as will your and reimbursement)/3

Right now, accurate insulin dosing is difficult. The ALRT algorithm helps. The predictive A1c helps even more/4